Provided by Tiger Fintech (Singapore) Pte. Ltd.

Halozyme Therapeutics

49.92
-16.6600-25.02%
Volume:7.86M
Turnover:401.98M
Market Cap:6.15B
PE:13.28
High:57.99
Open:57.76
Low:48.15
Close:66.58
Loading ...

Stock Track | Halozyme Therapeutics Plummets 20% After Leerink Partners Downgrades to Underperform

Stock Track
·
2 hours ago

Halozyme Therapeutics Cut to Underperform From Market Perform by Leerink Partners

Dow Jones
·
1 hour ago

Leerink Partners Downgrades Halozyme Therapeutics to Underperform From Market Perform, Price Target is $47

MT Newswires Live
·
2 hours ago

Halozyme Therapeutics, Inc : Morgan Stanley Raises Target Price to $73.00 From $67.00

THOMSON REUTERS
·
08 May

William O'Neil Initiates Halozyme Therapeutics at Buy

MT Newswires Live
·
08 May

Halozyme Therapeutics Up Over 17%, on Track for Record High Close -- Data Talk

Dow Jones
·
08 May

Halozyme Therapeutics Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
07 May

Stock Track | Halozyme Therapeutics Soars 8.33% Following Analyst Price Target Hikes

Stock Track
·
07 May

Stock Track | Halozyme Therapeutics Soars 6.77% Pre-market on Analyst Price Target Hikes

Stock Track
·
07 May

Morgan Stanley Raises Price Target on Halozyme Therapeutics to $73 From $67, Keeps Overweight Rating

MT Newswires Live
·
07 May

Wells Fargo Sticks to Its Hold Rating for Halozyme (HALO)

TIPRANKS
·
07 May

Stock Track | Halozyme Therapeutics Soars 6.10% After-Hours on Strong Q1 Results and Raised 2025 Guidance

Stock Track
·
07 May

Halozyme Therapeutics Q1 Adjusted EPS, Revenue Increase, Boosts 2025 Outlook; Shares Rise

MT Newswires Live
·
07 May

Halozyme Therapeutics Q1 Adj. EPS $1.11 Beats $0.94 Estimate, Sales $264.86M Beat $230.18M Estimate

Benzinga
·
07 May

BRIEF-Halozyme Therapeutics Q1 Adjusted EPS USD 1.11 Vs. IBES Estimate USD 0.94

Reuters
·
07 May

Halozyme Therapeutics Inc - Announces New $250 Million Share Repurchase

THOMSON REUTERS
·
07 May

Halozyme Therapeutics Inc FY2025 Shr View $5.00, REV View $1.20 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
07 May

Halozyme Raises 2025 Financial Guidance Ranges and Reports Strong First Quarter 2025 Results

THOMSON REUTERS
·
07 May